Fresenius SE & Co. KGaA Completes Full Acquisition of mAbxience Holding S.L.

On 1 October 2026, Fresenius SE & Co. KGaA announced the finalization of its purchase of the remaining 45 % stake in mAbxience Holding S.L. The transaction, valued at up to €750 million, included a contingent payment linked to the regulatory approval of mAbxience’s production sites. With the completion of this deal, Fresenius now owns 100 % of the biosimilar platform, thereby consolidating its biopharma operations across the entire value chain—from research and development to manufacturing and marketing.

Strategic Rationale

The biosimilars market is projected to grow rapidly as patent exclusivities on numerous biologic therapies expire over the next decade. By securing full ownership of mAbxience, Fresenius aims to:

  • Increase Control Over Investment Decisions: Full equity allows the company to align R&D and manufacturing budgets with its long‑term corporate objectives without external stakeholder constraints.
  • Optimize Production Capacity: Direct oversight of production facilities enables Fresenius to scale manufacturing in response to market demand, thereby reducing lead times for product launches.
  • Enhance Time‑to‑Market: With no need to negotiate joint decision‑making with minority stakeholders, Fresenius can expedite the rollout of new biosimilars.
  • Maximize Economic Returns: All revenue and cost benefits derived from the platform will accrue to Fresenius, improving return‑on‑investment metrics for shareholders.

Regulatory and Safety Considerations

The contingent payment structure underscores Fresenius’s commitment to compliance and quality. The payment is triggered only upon successful regulatory approval of mAbxience’s production sites by the relevant authorities (e.g., EMA, FDA, and national regulatory agencies). This mechanism serves several purposes:

  • Risk Mitigation: It aligns the payment with demonstrable regulatory success, reducing Fresenius’s exposure to potential non‑compliance risks.
  • Quality Assurance: By tying financial incentives to regulatory milestones, Fresenius reinforces adherence to Good Manufacturing Practice (GMP) standards.
  • Patient Safety: Regulatory approval of manufacturing facilities is a prerequisite for ensuring that biosimilar products meet the stringent safety and efficacy criteria required for market authorization.

Expected Impact on Patient Care and Healthcare Systems

Fresenius’s expanded biosimilar portfolio is anticipated to:

  • Improve Access to Affordable Biologics: Biosimilars typically offer cost savings relative to originator biologics, potentially lowering treatment costs for patients and payers.
  • Support Therapeutic Continuity: A robust domestic manufacturing network mitigates supply disruptions, ensuring consistent availability of essential therapies.
  • Encourage Innovation: With increased capital and operational flexibility, Fresenius can invest in next‑generation biosimilar candidates, fostering therapeutic advancement.

Conclusion

The full acquisition of mAbxience by Fresenius SE & Co. KGaA represents a decisive step toward consolidating the company’s position in the biosimilars arena. By securing end‑to‑end control over the production and commercialization of high‑quality biosimilar products, Fresenius is poised to deliver enhanced value to patients, healthcare providers, and the broader health economy, while aligning with its broader strategy of fostering biopharmaceutical innovation.